Chlormethenmadinone acetate

Chlormethenmadinone acetate (CMA) is a progestin that is used in hormonal contraception and hormone therapy. It is a derivative of progesterone, a naturally occurring female sex hormone. CMA is a potent progestogen and has antiandrogenic effects, which can be beneficial in the treatment of conditions such as polycystic ovary syndrome (PCOS) and endometriosis.

Pharmacology

CMA acts by binding to and activating the progesterone receptor, which in turn inhibits the release of gonadotropins from the pituitary gland. This prevents ovulation and alters the lining of the uterus, making it less likely for a fertilized egg to implant and grow. In addition, CMA has antiandrogenic properties, meaning it can block the effects of androgens (male sex hormones) in the body. This can be useful in treating conditions that are caused or worsened by excess androgens, such as PCOS and certain types of acne and hirsutism.

Clinical use

CMA is used in hormonal contraception, either alone or in combination with an estrogen. It is also used in hormone therapy for menopausal symptoms and in the treatment of gynecological disorders such as endometriosis and PCOS. In addition, it has been used to treat certain types of hormone-dependent cancers.

Side effects

Like all medications, CMA can cause side effects. These may include nausea, breast tenderness, changes in menstrual bleeding patterns, and mood changes. More serious side effects can include an increased risk of blood clots, stroke, and heart attack, particularly in women who smoke or have other risk factors.

See also

• Progestin
• Hormonal contraception
• Hormone therapy
• Progesterone receptor
• Gonadotropin
• Pituitary gland
• Androgen
• Polycystic ovary syndrome
• Endometriosis
• Acne
• Hirsutism

• 
  Chlormethenmadinone acetate